Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

Autor: Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M

Publikováno v: International Journal of COPD, Vol Volume 19, Pp 2729-2737 (2024)

Shigeo Muro,1 Munehiro Seki,2 John R Hurst,3 David Petullo,4 Jonathan Marshall,5 Karin Bowen,4 Patrick F Darken,4 Elizabeth A Duncan,6 Ayman Megally,4 Mehul Patel5 1Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 2AstraZenec

Externí odkaz: https://doaj.org/article/8de0f2083c9f4722aa9f67757668d26c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.

Autor: Liu T; Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Neuner R; Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Thompson A; Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drug, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Pottackal G; Division of Biometrics III, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Petullo D; Division of Biometrics III, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Liu J; Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Nikolov N; Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Sahajwalla C; Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Doddapaneni S; Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA., Chen J; Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, 4137Food and Drug Administration, Silver Spring, MD, USA.

Publikováno v: Lupus [Lupus] 2022 Apr; Vol. 31 (4), pp. 424-432. Date of Electronic Publication: 2022 Mar 03.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.